RT journal article
T1 Association between chronic pain medications and the severity and mortality of COVID-19: Study protocol for a case-population study
A1 Serrano Afonso, Andrés Ancor
A1 Pérez Hernández, Concepción
A1 Ochoa Mazarro, Dolores
A1 Román Martínez, Manuel
A1 Failde Martínez, Inmaculada
A1 Montes Pérez, Antonio
A1 López Pais, Pablo
A1 Cánovas Martínez, Luz
A1 Revuelta Rizo, Miren
A1 Padilla del Rey, María Luz
A1 Peiró Perió, Ana
A1 Aberasturi Fueyo, Teresa
A1 Margarit Ferrí, César
A1 Rojo Rodríguez, Elena
A1 Mendiola de la Osa, Agustín
A1 Muñoz Martinez, Manuel Jesús
A1 Domínguez Bronchal, María Jesús
A1 Herrero Trujillano, Manuel
A1 Cid Calzada, José
A1 Fabregat-Cid, Gustavo
A1 Hernández-Cádiz, María José
A1 Mareque Ortega, Manuel
A1 Gómez-Caro Álvarez Palencia, Leticia
A1 Mayoral Rojals, Víctor
A2 BiomedicinaBiotecnología y Salud Pública
AB In patients with coronavirus disease 2019 (COVID-19) infection, common drugs may exacerbate symptoms and negatively impact outcomes. However, the role of chronic medications on COVID-19 effects remains poorly understood. We hypothesized that certain chronic pain medications would influence outcomes in patients with COVID-19.The main aim is to assess the effect of these medications on the course of the disease in COVID-19 patients. Secondary aims are tocompare disease severity and outcomes in patients with COVID-19 receiving chronic treatment with analgesics or other medicationsversus untreated patients and to determine prevalence of chronic pain medications in specific subgroups of hospitalized patients forCOVID-19.Multicenter case-population study in 15 care centers for patients ≥18years of age diagnosed and hospitalized with COVID-19.Controls will include patients treated at participating centers for chronic pain during the six-month period prior to March 15th, 2020.Each case will be age- and sex-matched to 10 controls. Patients will be grouped according to disease severity criteria. The primaryoutcome measures in patients admitted for COVID-19 will be:1. statistical association between chronic pain medication and disease severity;2. association between chronic pain treatment and survival.Secondary outcome measures include:1. prevalence of chronic pain medications in patients with COVID-19 by age and sex;2. prevalence of chronic pain medications in patients with COVID-19 vs controls.Patients and controls will be paired by age, sex, and geographic residence. Odds ratios with 95% confidence intervals will becalculated to determine the association between each drug and clinical status. Univariate and multivariate analyses will be performed.This is a study protocol. Data is actually being gathered and results are yet not achieved. There is no numerical data presented, sothe conclusions cannot be considered solid at this point.Pain medications are likely to influence severity of COVID-19 and patient survival. Identifying those medications that are mostclosely associated with severe COVID-19 will provide clinicians with valuable data to guide treatment and reduce mortality rates andthe long-term sequelae of the disease.
PB NLM (Medline)
SN 1536-5964
YR 2021
FD 2021
LK http://hdl.handle.net/10498/27116
UL http://hdl.handle.net/10498/27116
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 14-nov-2026